Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Meridian Bioscience, Inc. (VIVO): Are Hedge Funds Right About This Stock?

We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds’ top 3 stock picks returned 41.7% this year and beat the S&P 500 ETFs by 14 percentage points. Investing in index funds guarantees you average returns, not superior returns. We are looking to generate superior returns for our readers. That’s why we believe it isn’t a waste of time to check out hedge fund sentiment before you invest in a stock like Meridian Bioscience, Inc. (NASDAQ:VIVO).

Meridian Bioscience, Inc. (NASDAQ:VIVO) shareholders have witnessed a decrease in hedge fund sentiment lately. Our calculations also showed that VIVO isn’t among the 30 most popular stocks among hedge funds (click for Q3 rankings and see the video below for Q2 rankings).
5 Most Popular Stocks Among Hedge Funds
Video: Click the image to watch our video about the top 5 most popular hedge fund stocks.

At the moment there are several signals investors have at their disposal to value their holdings. A duo of the most underrated signals are hedge fund and insider trading interest. We have shown that, historically, those who follow the best picks of the top fund managers can outperform the market by a healthy margin (see the details here).

Paul Marshall Marshall Wace

Paul Marshall of Marshall Wace

We leave no stone unturned when looking for the next great investment idea. For example Europe is set to become the world’s largest cannabis market, so we check out this European marijuana stock pitch. One of the most bullish analysts in America just put his money where his mouth is. He says, “I’m investing more today than I did back in early 2009.” So we check out his pitch. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. We also rely on the best performing hedge funds‘ buy/sell signals. Let’s review the key hedge fund action encompassing Meridian Bioscience, Inc. (NASDAQ:VIVO).

How have hedgies been trading Meridian Bioscience, Inc. (NASDAQ:VIVO)?

At the end of the third quarter, a total of 16 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of -6% from the second quarter of 2019. The graph below displays the number of hedge funds with bullish position in VIVO over the last 17 quarters. So, let’s find out which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

More specifically, Renaissance Technologies was the largest shareholder of Meridian Bioscience, Inc. (NASDAQ:VIVO), with a stake worth $31.1 million reported as of the end of September. Trailing Renaissance Technologies was D E Shaw, which amassed a stake valued at $6.1 million. Marshall Wace, Arrowstreet Capital, and GAMCO Investors were also very fond of the stock, becoming one of the largest hedge fund holders of the company. In terms of the portfolio weights assigned to each position Zebra Capital Management allocated the biggest weight to Meridian Bioscience, Inc. (NASDAQ:VIVO), around 0.26% of its 13F portfolio. Tudor Investment Corp is also relatively very bullish on the stock, dishing out 0.03 percent of its 13F equity portfolio to VIVO.

Seeing as Meridian Bioscience, Inc. (NASDAQ:VIVO) has faced falling interest from hedge fund managers, logic holds that there exists a select few hedge funds who sold off their positions entirely by the end of the third quarter. Intriguingly, Donald Sussman’s Paloma Partners sold off the biggest position of the 750 funds monitored by Insider Monkey, worth about $0.5 million in stock. Minhua Zhang’s fund, Weld Capital Management, also cut its stock, about $0.3 million worth. These bearish behaviors are interesting, as total hedge fund interest fell by 1 funds by the end of the third quarter.

Let’s go over hedge fund activity in other stocks – not necessarily in the same industry as Meridian Bioscience, Inc. (NASDAQ:VIVO) but similarly valued. We will take a look at Green Plains Inc. (NASDAQ:GPRE), Extraction Oil & Gas, Inc. (NASDAQ:XOG), Global Medical REIT Inc. (NYSE:GMRE), and El Pollo LoCo Holdings Inc (NASDAQ:LOCO). This group of stocks’ market valuations are closest to VIVO’s market valuation.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
GPRE 16 100604 0
XOG 17 57652 0
GMRE 8 15835 -5
LOCO 10 9183 -1
Average 12.75 45819 -1.5

View table here if you experience formatting issues.

As you can see these stocks had an average of 12.75 hedge funds with bullish positions and the average amount invested in these stocks was $46 million. That figure was $53 million in VIVO’s case. Extraction Oil & Gas, Inc. (NASDAQ:XOG) is the most popular stock in this table. On the other hand Global Medical REIT Inc. (NYSE:GMRE) is the least popular one with only 8 bullish hedge fund positions. Meridian Bioscience, Inc. (NASDAQ:VIVO) is not the most popular stock in this group but hedge fund interest is still above average. This is a slightly positive signal but we’d rather spend our time researching stocks that hedge funds are piling on. Our calculations showed that top 20 most popular stocks among hedge funds returned 37.4% in 2019 through the end of November and outperformed the S&P 500 ETF (SPY) by 9.9 percentage points. Unfortunately VIVO wasn’t nearly as popular as these 20 stocks and hedge funds that were betting on VIVO were disappointed as the stock returned -3.6% during the fourth quarter (through the end of November) and underperformed the market. If you are interested in investing in large cap stocks with huge upside potential, you should check out the top 20 most popular stocks among hedge funds as many of these stocks already outperformed the market so far this year.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.